Skip to main content

Cadrenal Therapeutics, Inc.

CVKD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001937993

In the last 90 days, Cadrenal Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.8K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cadrenal Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $22.4K in total
Insiders trading
1
Net value
−$22.4K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cadrenal Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cadrenal Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Pham Quang XChairman and CEO98,589Jul 1, 202614
Szot Matthew KChief Financial Officer0Dec 31, 20255
Golden Lee ScottDirector–Dec 3, 20251
Ferguson James J. IIIChief Medical Officer–Feb 6, 20250
Murphy John RaymondDirector614,792Jan 24, 20250
Wilson GlynnDirector50,000Jan 24, 20250
Zelenkofske StevenDirector–Jan 24, 20250
Cole Jeffrey ScottChief Operating Officer–Jan 24, 20250
Lisicki RobertDirector–Jan 24, 20250
Losordo Douglas WChief Medical Officer–Jan 19, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 1, 2026 (view filing)9:52 PM ETJun 292 daysPham Quang XChairman and CEOSSale−7.40K$3.03−$22.4K−7.0%98.6K after10b5-1
Jun 26, 2026 (view filing)Jun 25-261 dayPham Quang XChairman, CEO and Interim CFOSSale−11.2K$3.04−$33.9K−9.5%106.0K after2 lots10b5-1
Jun 24, 2026 (view filing)Jun 22-232 daysPham Quang XChairman, CEO and Interim CFOSSale−11.4K$3.48−$39.8K−8.9%117.1K after2 lots10b5-1
Jun 18, 2026 (view filing)Jun 16-172 daysPham Quang XChairman, CEO and Interim CFOSSale−4.13K$3.18−$13.1K−3.1%128.6K after2 lots10b5-1
Jun 15, 2026 (view filing)Jun 11-154 daysPham Quang XChairman, CEO and Interim CFOSSale−18.1K$3.88−$70.4K−12.0%132.7K after3 lots
Jun 10, 2026 (view filing)Jun 8-102 daysPham Quang XChairman, CEO and Interim CFOSSale−22.4K$4.17−$93.3K−12.9%150.8K after3 lots10b5-1
Jun 5, 2026 (view filing)Jun 3-52 daysPham Quang XCEO and ChairmanSSale−8.29K$4.37−$36.2K−4.6%173.2K after3 lots10b5-1
Jun 2, 2026 (view filing)May 29-Jun 24 daysPham Quang XCEO and ChairmanSSale−652$4.72−$3.07K−0.4%181.5K after2 lots10b5-1
May 29, 2026 (view filing)May 11-2818 daysLatePham Quang XCEO and ChairmanSSale−12.8K$5.44−$69.5K−6.5%182.2K after3 lots10b5-1
May 26, 2026 (view filing)May 224 daysPham Quang XCEO and ChairmanSSale−1.17K$5.69−$6.63K−0.6%194.9K after10b5-1
Dec 31, 2025 (view filing)Dec 292 daysSzot Matthew KChief Financial OfficerSSale−9.93K$6.97−$69.2K−100.0%0 after10b5-1
Oct 28, 2025 (view filing)Oct 24-274 daysSzot Matthew KChief Financial OfficerSSale−3.60K$13.99−$50.4K−26.6%9.93K after2 lots10b5-1
Oct 28, 2025 (view filing)Oct 24-274 daysPham Quang XCEO and ChairmanSSale−2.44K$14.01−$34.2K−1.2%196.1K after2 lots10b5-1
Oct 14, 2025 (view filing)Oct 9-135 daysPham Quang XCEO and ChairmanSSale−3.60K$14.09−$50.7K−1.8%198.5K after2 lots10b5-1
Oct 14, 2025 (view filing)Oct 9-135 daysSzot Matthew KChief Financial OfficerSSale−3.49K$14.03−$49.0K−20.5%13.5K after2 lots10b5-1
Oct 7, 2025 (view filing)Oct 61 daySzot Matthew KChief Financial OfficerSSale−107$13.99−$1.50K−0.6%17.0K after10b5-1
Oct 3, 2025 (view filing)Oct 21 dayPham Quang XCEO and ChairmanSSale−500$14.13−$7.07K−0.2%202.1K after10b5-1
Oct 1, 2025 (view filing)Sep 29-Oct 12 daysSzot Matthew KChief Financial OfficerSSale−1.80K$13.99−$25.2K−9.5%17.1K after2 lots10b5-1
Oct 1, 2025 (view filing)Sep 29-Oct 12 daysPham Quang XCEO and ChairmanSSale−1.30K$14.01−$18.2K−0.6%202.6K after2 lots10b5-1
Sep 26, 2025 (view filing)Sep 24-252 daysSzot Matthew KChief Financial OfficerSSale−12.4K$14.04−$174.1K−39.6%18.9K after2 lots10b5-1
Sep 26, 2025 (view filing)Sep 24-252 daysPham Quang XCEO and ChairmanSSale−9.37K$14.06−$131.8K−4.4%203.9K after2 lots10b5-1
Aug 29, 2025 (view filing)Aug 27-282 daysSzot Matthew KChief Financial OfficerSSale−2.00K$14.00−$28.0K−6.0%31.3K after2 lots10b5-1
Aug 29, 2025 (view filing)Aug 27-282 daysPham Quang XCEO and ChairmanSSale−5.03K$13.99−$70.4K−2.3%213.3K after2 lots10b5-1
Oct 6, 2023 (view filing)Oct 4-52 daysMurphy John RaymondDirectorPPurchase+20.0K$0.6987+$14.0K+3.4%614.8K after2 lots
Sep 6, 2023 (view filing)Sep 51 dayPham Quang XCEO and ChairmanPPurchase+40.0K$0.905+$36.2K+1.2%3.41M after2 lots
Sep 5, 2023 (view filing)Sep 14 daysPham Quang XCEO and ChairmanPPurchase+70.0K$0.9129+$63.9K+2.1%3.37M after5 lots
Mar 22, 2023 (view filing)Mar 211 dayMurphy John RaymondDirectorPPurchase+10.0K$1.39+$13.9K+1.7%594.8K after
Mar 16, 2023 (view filing)Mar 16Same dayMurphy John RaymondDirectorPPurchase+20.0K$1.67+$33.4K+3.6%574.8K after